ClinicalTrials.gg
CompletedNCT06531538Updated Mar 11, 2026

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

A Phase 2 interventional study of PG4 and 20-valent pneumococcal conjugate vaccine (20vPnC) in Pneumococcal Disease, sponsored by Pfizer. Completed at 39 sites in 2 countries. Open to participants aged 12 Months to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
12 Months to 15 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.

Enrollment
47th of 57
225 · median 570
Started
2024
with 2 others
Phase 2
7 of 75
none open now
Registered
66th of 75
by date

Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 66th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 12 Months to 15 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Pneumococcal Infections by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers.

Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group.

At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during some clinic visits.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
12 Months to 15 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female toddlers ≥12 to ≤15 months of age at the time of consent.
  • Healthy toddlers determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.
  • Have received 3 infant doses of 20vPnC with the last dose administered >56 days before enrollment into the study. Documented confirmation of receipt will be collected prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis).
  • Major known congenital malformation or serious chronic disorder.
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Previous vaccination with any licensed or investigational pneumococcal vaccine (other than 20vPnC) or planned receipt during study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    PG4 1-Dose Group

    Participants to receive a single injection of Multivalent Pneumococcal Vaccine

    Biological: PG4

  • Experimental
    PG4 2-Dose Group

    Participants to receive two injections of Multivalent Pneumococcal Vaccine

    Biological: PG4

  • Active comparator
    20-valent pneumococcal conjugate vaccine (20vPnC)

    Participants to receive a single injection of 20-valent pneumococcal conjugate vaccine (20vPnC).

    Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prespecified local reactions within 7 days after each dose

    Prespecified local reactions (redness, swelling, and pain at the injection site) after each dose

    Time frame: 7 days after each dose

  2. Percentage of participants reporting prespecified systemic events within 7 days after each dose

    Prespecified systemic events (fever, decreased appetite, drowsiness/increased sleep, and irritability) after each dose

    Time frame: 7 days after each dose

  3. Percentage of participants reporting Adverse Events (AEs) within 1 month after the last assigned vaccination

    Adverse events occurring within 1 month after the last assigned vaccination

    Time frame: From signing of ICD to 1 month after last assigned vaccination

  4. Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccination

    SAEs occurring from Dose 1 through 6 months after the last assigned vaccination

    Time frame: From signing of ICD to 6 months after last assigned vaccination

Secondary outcomes

  1. Pneumococcal serotype specific IgG concentrations

    Pneumococcal IgG GMCs 1 month after the last assigned vaccination

    Time frame: 1 month after last assigned vaccination

07

Study locations

39 sites
  • Emerson Clinical Research Institute
    Washington D.C., District of Columbia 20009, United States
  • Bio-Medical Research LLC
    Miami, Florida 33144, United States
  • Tekton Research, LLC.
    Chamblee, Georgia 30341, United States
  • Javara - Privia Medical Group Georgia - Fayetteville
    Fayetteville, Georgia 30214, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • The Iowa Clinic
    Ankeny, Iowa 50023, United States
  • Louisiana State University Health Sciences Shreveport - Fairfield avenue
    Shreveport, Louisiana 71101, United States
  • Louisiana State University Health Sciences Shreveport
    Shreveport, Louisiana 71103, United States
  • Ochsner/LSU Health Ambulatory Care Center
    Shreveport, Louisiana 71103, United States
  • University of Maryland, Baltimore - Institutional Review Board
    Baltimore, Maryland 21201, United States
  • University of Maryland, Baltimore, Center for Vaccine Development and Global Health
    Baltimore, Maryland 21201, United States
  • The Pediatric Center
    Columbia, Maryland 21045, United States
  • Atrium Health - Strive Vaccine Research Clinic
    Charlotte, North Carolina 28207, United States
  • Atrium Health-Myers Park
    Charlotte, North Carolina 28207, United States
  • Duke Vaccine and Trials Unit
    Durham, North Carolina 27703, United States
  • Durham Pediatrics at North Duke Street
    Durham, North Carolina 27704, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Atrium Health-Matthews
    Matthews, North Carolina 28105, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Carolina Family Care
    Charleston, South Carolina 29414, United States
  • MUSC Children's Health
    Charleston, South Carolina 29414, United States
  • Carolina Family Care
    Summerville, South Carolina 29486, United States
  • MUSC Children's Health
    Summerville, South Carolina 29486, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Pediatric Clinical Trials of Tennessee, LLC
    Tullahoma, Tennessee 37388, United States
  • Javara - Privia Medical Group North Texas - Dallas
    Dallas, Texas 75230, United States
  • Oak Cliff Research Company, LLC
    Dallas, Texas 75252, United States
  • Oak Cliff Research Company, LLC
    Dallas, Texas 75287, United States
  • Mercury Clinical Research - Houston
    Houston, Texas 77054, United States
  • DM Clinical Research - Kool Kids Pediatrics
    Houston, Texas 77065, United States
  • Kool Kids Pediatrics
    Houston, Texas 77065, United States
  • Mercury Clinical Research - Sunrise Pediatrics
    Houston, Texas 77077, United States
  • Mercury Clinical Research - Pediatric Associates
    Houston, Texas 77087, United States
  • University of Texas Medical Branch
    League City, Texas 77573, United States
  • Mercury Clinical Research - North Houston Internal Medicine & Pediatric Clinic
    Tomball, Texas 77375, United States
  • Ponce Medical School Foundation Inc.
    Ponce, 00716, Puerto Rico
  • BRCR Medical Center - Ponce
    Ponce, 00717, Puerto Rico
  • BRCR Global Puerto Rico
    San Juan, 00907-1509, Puerto Rico
  • CMRC Headlands, LLC
    San Juan, 00918, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Feb 2026, 18 months.

Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Aug 1, 2024
StartActual
Jul 30, 2024
Primary completionActual
Feb 9, 2026
CompletionActual
Feb 9, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06531538
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Jul 30, 2024
Primary completion
Feb 9, 2026
Completion
Feb 9, 2026
Last update
Mar 11, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion